Final height in Italian patients with congenital hypothyroidism detected by neonatal screening: a 20-year observational study

Italian Journal of Pediatrics

Maria Felicia Faienza⁴  Mariacarolina Salerno³  Luciano Cavallo⁴  Filippo De Luca¹  Raffaella Di Mase³  Giulia Maria Tronconi⁵  Pietro Pio Popolo²  Rosa Lapolla²  Giovanna Weber⁵  Malgorzata Wasniewska¹  Maria Cristina Vigone⁵  Maurizio Delvecchio⁴ 

[1] Department of Pediatrics, University of Messina, Messina, Italy;Department of Pediatrics, University of Foggia, Foggia, Italy;Pediatric Section-Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy;Section of Pediatrics, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy;Department of Pediatrics Endocrinology, IRCCS Vita-Salute San Raffaele University, Milan, Italy

关键词: Obesity;    Final height;    Growth;    Thyroid;    Secular trend;    Congenital Hypothyroidism;   

Others  :  1232055
DOI  :  10.1186/s13052-015-0190-y

 received in 2015-07-18, accepted in 2015-10-16,  发布年份 2015

【 摘 要 】

Background

Linear growth and final height are reported as normal in congenital hypothyroid patients in the neonatal screening era.

Methods

We evaluated the final height in 215 patients with congenital hypothyroidism to assess if it improved over the last 2 decades.

Results

Final height (-0.1 ± 1.0 SDS) was higher than target height (-0.8 ± 1.0 SDS, p < 0.001) and not different among the 4 quartiles for birthdate. It was correlated with target height (r ²  = 0.564, p < 0.001) and height at puberty onset (r ²  = 0.685, p < 0.001), but not with age at diagnosis or the starting LT4/kg/day dose. The curve fitting analysis showed that the age at diagnosis progressively decreased during the 20-year study period, while the target height and the starting LT4/kg/day increased. Final height was not affected by the birthdate, the age at diagnosis, the starting LT4 dose.

Conclusions

The final height is higher than the target height, but despite the improvement in the screening and the treatment, it did not improve over the last 20 years. These findings are in keeping with the described secular trend and suggest that earlier diagnosis and replacement therapy do not significantly modify final height in these patients.

【 授权许可】

   
2015 Delvecchio et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Rose SR, Brown RS, Foley T, et al.: American Academy of PediatricsSection on Endocrinology and Committee on Genetics, American Thyroid AssociationPublic Health Committee, Lawson Wilkins Pediatric Endocrine Society: Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006, 117:2290-303.
• [2]Cassio A, Corbetta C, Antonozzi I, Calaciura F, Caruso U, Cesaretti G, et al.: The Italian screening program for primary congenital hypothyroidism: actions to improve screening, diagnosis, follow-up, and surveillance. J Endocrinol Invest 2013, 36(Suppl 3):195-203.
• [3]Dickerman Z, De Vrie L: Prepubertal and pubertal growth, timing and duration of puberty and attained adult height in patients with congenital hypothyroidism (CH) detected by the neonatal screening programme for CH – a longitudinal study. Clin Endocrinol 1997, 47:649-54.
• [4]Salerno M, Micillo M, Di Maio S, Capalbo S, Ferri P, Lettiero T, et al.: Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol 2001, 145(Suppl 4):377-83.
• [5]Bain P, Toublanc JE: Adult height in congenital hypothyroidism: prognostic factors and the importance of compliance with treatment. Horm Res 2002, 58:136-42.
• [6]Adachi M, Asakura Y, Tachibana K: Final height and pubertal growth in Japanese patients with congenital hypothyroidism detected by neonatal screening. Acta Paediatr 2003, 92:698-703.
• [7]Delvecchio M, Salerno M, Acquafredda A, Zecchino C, Fico F, Manca F, et al.: Factors predicting final height in early treated congenital hypothyroid patients. Clin Endocrinol (Oxf) 2006, 65(Suppl 5):693-7.
• [8]Léger J: Congenital hypothyroidism: a clinical update of long-term outcome in young adults. Eur J Endocrinol 2015, 172(Suppl 2):R67-77.
• [9]Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G: Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 1996, 81:222-7.
• [10]Salerno M, Militerni R, Di Maio S, Bravaccio C, Gasparini N, Tenore A: Intellectual outcome at 12 years of age in congenital hypothyroidism. Eur J Endocrinol 1999, 141:105-110.
• [11]Fisher DA: The importance of early management in optimizing IQ in infants with congenital hypothyroidism. J Pediatr 2000, 136:273-4.
• [12]Salerno M, Militerni R, Bravaccio C, Micillo M, Capalbo S, Di Maio S, et al.: Effect of different starting doses of l-thyroxine on growth and intellectual outcome at 4 years of age in congenital hypothyroidism. Thyroid 2002, 12:45-52.
• [13]Wasniewska M, De Luca F, Cassio A, Oggiaro N, Gianino P, Delvecchio M, et al.: In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first Year of life irrespective of other variables related to treatment. Eur J Endocrinol 2003, 149(Suppl 1):1-6.
• [14]Selva KA, Harper A, Downs A, Blasco PA, Lafranchi SH: Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial t4 dose and time to reach target T4 and TSH. J Pediatr 2005, 147:775-80.
• [15]Bongers-Schokking JJ, de Muinck K-SSMPF: Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioural development in children with congenital hypothyroidism. J Pediatr 2005, 147:768-74.
• [16]Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, et al.: ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE; Congenital Hypothyroidism Consensus Conference Group. Congenital Hypothyroidism Consensus Conference Group, European society for paediatric endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014, 99(Suppl 2):363-84.
• [17]Kempers MJ: van der Sluijs Veer L, Nijhuis-van der Sanden RW, Lanting CI, Kooistra L, Wiedijk BM, Last BF, de Vijlder JJ, Grootenhuis MA, Vulsma T. Neonatal screening for congenital hypothyroidism in The Netherlands: cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab 2007, 92:919-24.
• [18]Olney RS, Grosse SD, Vogt RF Jr: Prevalence of congenital hypothyroidism—current trends and future directions: workshop summary. Pediatrics 2010, 125:31-6.
• [19]Kempers MJ, Van der Sluijs Veer L, der Sanden MW N-v, Kooistra L, Wiedijk BM, Faber I, et al.: Intellectual and motor development of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2006, 91:418-24.
• [20]Léger J, Ecosse E, Roussey M, Lanoë JL, Larroque B: French Congenital Hypothyroidism Study Group: Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. J Clin Endocrinol Metab 2011, 96(Suppl 6):1771-82.
• [21]Donaldson M, Jones J: Optimising outcome in congenital hypothyroidism; current opinions on best practice in initial assessment and subsequent management. J Clin Res Pediatr Endocrinol 2013, 5(Suppl 1):13-22.
• [22]Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch Dis Child 1966, 41:613-35.
• [23]Traggiai C, Stanhope R: Disorders of pubertal development. Best Pract Res Clin Obstet Gynaecol 2003, 17(Suppl 1):41-56.
• [24]Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, et al.: Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 2002, 56:171-80.
• [25]Hanukoglu A, Perlman K, Shamis I, Brnjac L, Rovet J, Daneman D: Relationship of etiology to treatment in congenital hypothyroidism. J Clin Endocrinol Metab 2001, 86:186-91.
• [26]Delvecchio M, Faienza MF, Acquafredda A, Zecchino C, Peruzzi S, Cavallo L: Longitudinal assessment of levo-thyroxine therapy for congenital hypothyroidism: relationship with aetiology, bone maturation and biochemical features. Horm Res 2007, 68(Suppl 3):105-12.
• [27]Delvecchio M, Salerno M, Vigone MC, Wasniewska M, Popolo PP, Lapolla R, et al. Levothyroxine requirement in congenital hypothyroidism: a 12-year longitudinal study. Endocrine. 2015, in press.
• [28]Hauspie RC, Vercauteren M, Susanne C: Secular changes in growth and maturation: an update. Acta Paediatr Suppl 1997, 423:20-7.
• [29]Cole TJ: Secular trends in growth. Proc Nutr Soc 2000, 59:317-24.
• [30]Cole TJ: The secular trend in human physical growth: a biological view. Econ Hum Biol 2003, 1:161-8.
• [31]Schmidt IM, Jorgensen MH, Michaelsen KF: Height of conscripts in Europe: is postneonatal mortality a predictor? Ann Hum Biol 1995, 22:57-67.
• [32]Larnkjaer A, Attrup SS, Schmidt IM, Horby JM, Fleischer MK: Secular change in adult stature has come to a halt in northern Europe and Italy. Acta Paediatr 2006, 95:754-5.
• [33]Danubio ME, Sanna E: Secular changes in human biological variables in Western countries: an updated review and synthesis. J Anthropol Sci 2008, 86:91-112.
• [34]Gohlke B, Woelfle J: Growth and puberty in German children: is there still a positive secular trend? Dtsch Arztebl Int 2009, 106:377-82.
• [35]Sanna E: Il secular trend in Italia. Antropo 2002, 3:23-49.
• [36]Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega AC, et al.: Use of national and international growth charts 14 for studying height in European children: development of up-to-date European height-for-age charts. PLoS One 2012, 7(Suppl 8):e42506.